ASX Health: 4D Medical jumps 16pc on lungs device rollout, Proteomics up 10pc on UK deal
Health & Biotech
Health & Biotech
Link copied to
The ASX 200 Health Index (XHJ) is down by 0.30% at the time of writing, compared to the broader index which is up by 0.30%.
Respiratory device specialist, 4D Medical (ASX:4DX), jumped 16% after announcing the rollout of its XV LVAS software with I-MED, Australia’s largest diagnostic imaging provider.
4D Medical’s XV Technology is used as a surveillance tool, monitoring the condition of patients’ lungs and responses to medicine.
First revenues from I-MED are expected to be received following installation at the first clinic in December.
“People living with or concerned about respiratory disease will have access to the world’s most advanced four-dimensional quantification and visualisation of their lungs,”said 4D Medical CEO Dr Andreas Fouras.
“This will enable them and their referring doctor to gain insights into lung function with the highest sensitivity.”
Meanwhile another diagnostics tech company, Proteomics (ASX:PIQ), surged 10.5% after it announced the signing of a two-year distribution deal with Apacor.
The agreement will bring PIQ’s PromarkerD test for diabetic kidney disease to patients in England, Scotland and Wales.
An estimated 4.8 million people or 7% of the British population live with diabetes, according to Diabetes UK.
The newly listed wound healing specialist is progressing its wound gel product, TR-987, towards a Phase III clinical trial.
The company said that initial market research highlights keen interest in its TR Pro+ product, a post-procedure gel to be used following minimally invasive cosmetic procedures.
The cannabis company has entered into a collaborative supply and toll processing deal for cannabis biomass extraction with Sun Pharma, the fourth largest specialty generic pharmaceutical company in the world.
Under the deal, ECS agreed to supply a minimum volume (600kg to 1750kg) of cannabis biomass over a five year period.
In return, Sun Pharma will install a CO2 extractor at its Port Fairy pharmaceutical facility.
The extractor will facilitate the production of decarboxylated winterised resin for ECS Botanics at a reduced rate.
ResApp Health (ASX:RAP) unchanged
ResApp’s Indian COVID-19 study has completed recruitment of 337 patients, including over 200 COVID-19 positive cases.
The company will be using data collected from these studies to develop and train machine learning algorithms to identify COVID-19 from cough sounds recorded on a smartphone.
Volpara’s FY22 half year revenues increased significantly from NZ$19.9m in the prior corresponding period (pcp) to NZ$29m.
The bottom net loss was NZ$8.5m, which was a 4% improvement on pcp.
Volpara assists in the delivery of personalised breast care, with its main market in the US.
Resonance Health (ASX:RHT) unchanged
The company has filed two additional Australian provisional patent applications covering the application of its novel Antisense Oligonucleotides (ASO).
ASOs are targeting three key members of the ‘cyclophilin’ protein family, an important group of proteins found across multiple diseases including microbial diseases, inflammatory disorders, as well as cancer.
At Stockhead we tell it like it is. While ECS Botanics and Volpara Health are Stockhead advertisers, they did not sponsor this article.